MARKET

AKBA

AKBA

Akebia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.370
-0.160
-4.53%
Pre Market: 3.300 -0.07 -2.08% 06:59 03/04 EST
OPEN
3.488
PREV CLOSE
3.530
HIGH
3.590
LOW
3.360
VOLUME
1
TURNOVER
--
52 WEEK HIGH
13.71
52 WEEK LOW
2.090
MARKET CAP
517.30M
P/E (TTM)
-1.2146
1D
5D
1M
3M
1Y
5Y
Anemia Drugs Market Size by Region 2021, Latest Trends, Key Players with Growth Rate, Total Revenues, Impact of COVID-19 on Global Industry and Recovery by 2027
The Express Wire · 4h ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 44,000 shares of Akebia's common stock o...
PR Newswire · 1d ago
Looking Into Akebia Therapeutics's Return On Capital Employed
During Q4, Akebia Therapeutics's (NASDAQ:AKBA) reported sales totaled $56.70 million. Despite a 47.01% in earnings, the company posted a loss of $85.40 million. In Q3, Akebia Therapeutics brought in $59.99 million in sales but lost $58.09 million in earnin...
Benzinga · 1d ago
Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
, /PRNewswire/ --  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that , Chief Executive Officer of Akebia, will participate in a fireside chat at the H.C. Wainwright ...
PR Newswire - PRF · 1d ago
Veterinary Medicine Market will Likely see Expanding of Marketable Business Segment | Bayer Animal Health, Ceva Animal Healthcare
marketresearch.biz · 2d ago
Anemia Drugs Market Demand Fuelled by Increased R and D Activities, Says Market.us
Mar 02, 2021 (WiredRelease via Comtex) -- A recent systematic review report on “Anemia Drugs Market is Expected to Thrive at Impressive CAGR by 2031 |...
marketresearch.biz · 2d ago
Makeup Base Market [Trending PDF] Excessive Growth Opportunities Estimated to Be Experienced 2021-2030 | Christian Dior SE, Loreal S.A
Mar 01, 2021 (WiredRelease via Comtex) -- A consciously conceived and designed business intelligence report titled Global Makeup Base market 2021 by...
marketresearch.biz · 3d ago
Global Anaemia Drugs Market to be Driven by Growing Prevalence of CKD Anaemia in the Forecast Period of 2021-2026
Feb 27, 2021 (AB Digital via COMTEX) -- The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses...
ABNewswire · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKBA. Analyze the recent business situations of Akebia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKBA stock price target is 7.00 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 283
Institutional Holdings: 105.88M
% Owned: 68.97%
Shares Outstanding: 153.50M
TypeInstitutionsShares
Increased
45
23.61M
New
53
-10.94M
Decreased
52
11.58M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Non-Executive Chairman/Independent Director
Adrian Adams
President/Chief Executive Officer/Director
John Butler
Chief Financial Officer/Senior Vice President/Treasurer
David Spellman
Chief Operating Officer/Senior Vice President
Michel Dahan
Senior Vice President/Secretary
Nicole Hadas
Senior Vice President
Steven Burke
Senior Vice President
Dell Faulkingham
Director
LeAnne Zumwalt
Independent Director
Mark Enyedy
Independent Director
Steven Gilman
Independent Director
Maxine Gowen
Independent Director
Michael Heffernan
Independent Director
Michael Rogers
Independent Director
Cynthia Smith
Independent Director
Myles Wolf
No Data
  • All
  • Financials
  • Insiders
More
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.